Acetylcholinesterase Inhibitor (AchEI) Prescribed/Recommended for Persons Diagnosed With Mild to Moderate Alzheimer's Disease
Identifying Attributes
Care Settings
Country
Publishing Organisation
Type of Quality Indicator
IOM Quality Dimension
Domain
Defining Attributes
Definition
Proportion of patients who are diagnosed with mild to moderate Alzheimer's disease and have acetylcholinesterase inhibitor (AChEI)prescribed/recommended
Numerator
Number of patients who are diagnosed with mild to moderate Alzheimer's disease and have acetylcholinesterase inhibitor (AChEI)prescribed/recommended
Denominator
Number of patients diagnosed with mild to moderate Alzheimer's disease
Exclusions
Use of Risk Adjustment
Risk Adjustments
None
Stratifications
85 years and under, over 85 years
Data Attributes
Type of Data Collection
Data Collection Methods
Data entered by participating sites into a secure online platform
Frequency of Data Collection
Frequency of Data Collection in Days
Reporting Methods
Yearly public report, six-monthly site reports, real time data via secure platform for sites
Reporting Frequency
Reporting Frequency in Days
Indicator Has Recommended Targets
Source and Reference Attributes
Evidence Source
Ward SA, Brodaty H, Lin X, Wallis K, Honardoost MA, Tsui A, Lassetter C, Rowe C, Anstey K, Brodtmann A, Chong T, Darling G, Inacio M, Jeon Y-H, Kain B, Loi S, McCabe M, Naismith S, Natarajan K, Nelson M, Newton L, Pietsch A, Quirke L, Rand E, Yates M, Arsenova V, Earnest A, McAloney K, Pourghaderi AR, Rahja M, Richardson J, Tan S and Ahern S. The Australian Dementia Network (ADNeT) Registry 2022 Annual Report. Monash University, School of Public Health and Preventive Medicine, May 2023.